Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)

Phase 2YA-101Positive

AI Analysis

Summary

Dasher Neuroscience completed patient enrollment in a Phase 2 global clinical trial of YA-101, its lead AI-derived drug candidate for Multiple System Atrophy. The company is an AI-driven biopharmaceutical firm focused on central nervous system drug discovery and development.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Patient enrollment completed in Phase 2 global clinical trial

Importance:6/10

Sentiment:

0.60

Phase 2CNSAI-drivenenrollment completionMSA

Related Companies

$7829

Read the original article

Published by PR Newswire Biotech on July 28, 2026 12:12 PM

Read Original